WMT

95.29

-0.26%↓

COST

970.95

-0.32%↓

KR

69.95

-2.79%↓

TGT

95.55

+1.53%↑

STZ

185.41

-0.3%↓

WMT

95.29

-0.26%↓

COST

970.95

-0.32%↓

KR

69.95

-2.79%↓

TGT

95.55

+1.53%↑

STZ

185.41

-0.3%↓

WMT

95.29

-0.26%↓

COST

970.95

-0.32%↓

KR

69.95

-2.79%↓

TGT

95.55

+1.53%↑

STZ

185.41

-0.3%↓

WMT

95.29

-0.26%↓

COST

970.95

-0.32%↓

KR

69.95

-2.79%↓

TGT

95.55

+1.53%↑

STZ

185.41

-0.3%↓

WMT

95.29

-0.26%↓

COST

970.95

-0.32%↓

KR

69.95

-2.79%↓

TGT

95.55

+1.53%↑

STZ

185.41

-0.3%↓

Search

Hims & Hers Health Inc

Открыт

СекторПотребительские товары
(защитный сектор)

27.6 -1.15

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

27.01

Макс.

28.73

Ключевые показатели

By Trading Economics

Доход

-50M

26M

Продажи

80M

481M

P/E

Средняя по отрасли

48.755

40.769

Прибыль на акцию

0.227

Рентабельность продаж

5.409

Сотрудники

1,637

EBITDA

-8.2M

19M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+71.36% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

5 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-5.2B

6B

Предыдущая цена открытия

28.75

Предыдущая цена закрытия

27.6

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Hims & Hers Health Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 апр. 2025 г., 22:38 UTC

Популярные акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 апр. 2025 г., 23:15 UTC

Главные движущие силы рынка

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 февр. 2025 г., 15:33 UTC

Главные движущие силы рынка

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 нояб. 2024 г., 19:07 UTC

Главные движущие силы рынка

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 окт. 2024 г., 15:02 UTC

Главные движущие силы рынка

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 окт. 2024 г., 11:28 UTC

Главные движущие силы рынка

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2 апр. 2025 г., 16:53 UTC

Главные новости

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 мар. 2025 г., 15:54 UTC

Главные новости

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 февр. 2025 г., 23:20 UTC

Отчет

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 февр. 2025 г., 12:00 UTC

Главные новости

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 дек. 2024 г., 17:16 UTC

Главные новости

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 дек. 2024 г., 15:14 UTC

Главные новости

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 дек. 2024 г., 15:02 UTC

Главные новости

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 дек. 2024 г., 13:47 UTC

Главные новости

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 дек. 2024 г., 07:00 UTC

Главные новости

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 окт. 2024 г., 14:45 UTC

Главные новости

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 окт. 2024 г., 13:12 UTC

Главные новости

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 окт. 2024 г., 11:45 UTC

Главные новости

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 окт. 2024 г., 10:14 UTC

Главные новости

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 авг. 2024 г., 17:52 UTC

Приобретения, слияния, поглощения

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 июн. 2024 г., 11:00 UTC

Главные новости
Приобретения, слияния, поглощения

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 мая 2024 г., 20:37 UTC

Отчет

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Сравнение c конкурентами

Изменение цены

Hims & Hers Health Inc Прогноз

Целевая цена

By TipRanks

71.36% рост

Прогноз на 12 месяцев

Средняя 45.77 USD  71.36%

Максимум 85 USD

Минимум 22 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для Hims & Hers Health Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

13 ratings

5

Покупка

6

Удержание

2

Продажа

Техническая оценка

By Trading Central

27.2 / 29Поддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.